TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referred for elective colonoscopy as outpatients~* Must be able to provide the informed consent~Exclusion Criteria:~* American Society of Anaesthesiologists (ASA) class \>2~* Pregnant women~* Difficult airway predictors (more than 2 ou Mallampati \>3)~* Allergy to propofol or its' components~* IV drugs abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Non-anesthesiologist propofol sedation (Type: EXPERIMENTAL): Bolus propofol sedation by non-anesthesiologist
- Anesthesiologist administered propofol (Type: ACTIVE_COMPARATOR): Propofol sedation administered by an anesthesiologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* De novo lesions~* elective PCI~* Only single coronary artery treated at this time~Exclusion Criteria:~* Those who meet the diagnostic criteria of acute myocardial infarction~* Patients with cardio-genic shock~* Patients with multiple organ failure~* Patients allergic to contrast~* Patients who can not tolerate dual antiplatelet therapy~* Patients who can't tolerate anticoagulation~* Recently infected patients~* Patients with hepatorenal dysfunction~* Thrombotic lesion of coronary artery~* Chronic total coronary occlusion lesion~* Patients with complex coronary bifurcation requiring two stent strategy~* Severe coronary calcified lesion~* Patients with percutaneous coronary angioplasty~* Patients with directional coronary atherectomy or rotational atherectomy~* Patients with drug coated balloon treatment~* Patients with bioabsorbable vascular scaffold implantation~* Previous percutaneous coronary intervention~* Previous coronary artery bypass graft~* Patients with active stage of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- prolonged continuous use of bivalirudine (Type: EXPERIMENTAL): A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
- bivalirudin use during ePCI (Type: OTHER): A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cancer Venous Thromboembolism (VTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with age ≥ 18 years or the otherwise legal lower age according to the country of residence;~* Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated;~* Cancer, other than basal-cell or squamous-cell carcinoma of the skin;~* Able to provide written informed consent.~Exclusion Criteria:~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE;~* Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;~* Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;~* Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban group (Type: EXPERIMENTAL): After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
- Dalteparin group (Type: ACTIVE_COMPARATOR): Participants receive Dalteparin treatment daily -solution for subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Cytogenetically proven Philadelphia chromosome positive chronic phase chronic myelogenous leukemia (CML) Initial diagnosis within the past 6 months No prior chemotherapy, including regimens used in peripheral blood progenitor cell (PBPC) mobilization for PBPC transplantation, for CML except hydroxyurea Must meet the following criteria: Blasts in peripheral blood and bone marrow less than 15% Blasts plus promyelocytes in peripheral blood and bone marrow less than 30% Basophils in peripheral blood less than 20% Platelet count at least 100,000/mm3 No extramedullary leukemic involvement except spleen or liver No patient for which a sibling bone marrow donor is available and allogeneic bone marrow transplantation is elected as first line therapy~PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT and SGPT no greater than 1.5 times (ULN) INR and PTT no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No angina No New York Heart Association class III or IV heart disease Other: No uncontrolled medical disease, such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, or infection HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix No history of noncompliance with medical regimens or potential for noncompliance~PRIOR CONCURRENT THERAPY: Biologic therapy: Concurrent leukapheresis allowed during the first month of study No concurrent allogeneic bone marrow transplantation Concurrent anagrelide allowed during the first 3 months of study Chemotherapy: See Disease Characteristics Concurrent hydroxyurea allowed only during the first 3 months of study Endocrine therapy: No concurrent systemic steroids for more than 2 weeks Radiotherapy: Not specified Surgery: Greater than 4 weeks since prior major surgery and recovered Other: No other prior investigational agents No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically and immunophenotypically confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL)~  * Relapsed or refractory disease~PATIENT CHARACTERISTICS:~* No known hypersensitivity to any of the study medications~* No uncontrolled infection~* No impaired organ function~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-smoking subjects~* 6-26 years of age~* Evidence of poor asthma control~* Adherence to ICS \< 50% of doses prescribed over a minimum of 3 months~* Baseline FEV1 \> 60% of predicted~* PC20 AMP \< 60 mg/ml~* Able to perform American Thoracic Society (ATS)-acceptable and reproducible spirometry~Exclusion Criteria:~* Cigarette smoking/use of marijuana~* Pregnancy~* Respiratory infections in past six weeks~* History of acute allergic reaction to asthma/allergy medication~* Total dose requirement of omalizumab more than 375 mg every two weeks~* Inability to withhold required medications before challenge~* Abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High-risk prostate cancer patients eligible for standard of care surgery~  * At least clinical T3a disease, and/or Gleason≥8, and/or Prostate-Specific Antigen (PSA) \>20, as per clinical assessment and routine guidelines~* Undergone standard of care conventional imaging (CT and/or MRI; bone scan and/or sodium fluoride (NaF) PET)~Exclusion Criteria:~* Definitive findings of systemic metastasis on conventional imaging.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FACBC PET-CT Imaging (Type: EXPERIMENTAL): Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient planed to undergo any liver surgical intervention~* age : over 18~* patients gave their written informed consent~Exclusion Criteria:~* pregnancy~* liver surgical intervention cancel upon surgical or medical decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigation arm (Type: EXPERIMENTAL): standard and respiratory-gated PET acquisitions  for patients included in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, age \>18 years, of all racial and ethnic origins.~* We are recruiting 12 normal or underweight (BMI \<25kg/m2), 12 overweight or obese (BMI 25-40 kg/m2), and 12 extremely obese (BMI \> 40 kg/m2) for this study. This index is calculated using the volunteer's height and weight (Formula: weight (lb) / \[height (in)\]2 x 703). Half of each group will be male; the other half will be female.~Exclusion Criteria:~* Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of sulfamethoxazole and trimethoprim on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of sulfamethoxazole and trimethoprim, so that the pregnancy and post-partum state would be a confounding variable.~* Abnormal liver function tests: transaminases\>10 times upper limit of normal, Alkaline phosphatase\>5 times upper limit of normal, total bilirubin\>5 times upper limit of normal.~* History of allergies to sulfones, sulfonamides or trimethoprim.~* Sulfones, sulfonamides or trimethoprim are contraindicated for any reason.~* Volunteers unwilling to comply with study procedures.~* Current suspected or documented ear infection, urinary tract infection, bronchitis, traveler's diarrhea, Pneumocystis carinii pneumonia, or any other bacterial infection.~* Volunteers with colon resection, gastric bypass, lap band, or any other conditions inhibiting gastric absorption of drug.~* Current or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by PI.~* Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment, unless waved by PI.~* Current use of medications contraindication with sulfamethoxazole/trimethoprim use: Bepridil, Cisapride, Dofetilide, Levomethadyl, Mesoridazine, Pimozide, Terfenadine, and Thioridazine. Other medications will be screened by study investigators to ensure the safety of research participants and maintain the quality of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sulfamethoxazole/trimethoprim (Type: EXPERIMENTAL): 2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males or females, 18-65 years of age at the time of Screening Visit~* Subject has at least 1-year history of migraines (with or without aura), according to the~* International Classification of Headache Disorder, 3rd Edition (ICHD3)~Key Exclusion Criteria:~* Pregnant or breast-feeding women~* Women of child-bearing potential not using or not willing to use highly effective contraception.~* Diagnosis of headache conditions other than migraine with or without aura, including diagnosis of basilar or hemiplegic migraines or cluster headache.~* History of coronary artery disease, coronary artery vasospasm (including Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary intervention, or cardiac surgery.~* History of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.~* Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or dependence, drug abuse or dependence, major psychiatric conditions (e.g. schizophrenia, psychosis or Bipolar disorder), dementia. Other significant neurological or psychiatric disorders (including other pain syndromes or risk of suicide) that in the opinion of the investigator might interfere with study participation and assessments or subject safety.~* Any clinically significant symptoms or conditions, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator might interfere with study assessments or safety of participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- STS101 (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electronic Cigarette Use in Young Adult Men and Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. be 18 through 29 years of age;~2. Smoke cigarettes;~3. have experience with e-cigarette use;~4. fluent in English;~5. have a functioning cell phone for personal use ;~6. have access to wireless networks at least once daily;~7. have self-reported good health.~Exclusion Criteria.~1. report serious medical illness;~2. are women who are currently/planning to be pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Survey Arm (Type: EXPERIMENTAL): Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heliox in Experimental Upper Airway Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteers of both sexes were recruited via posting in student forum of University of Witten/Herdecke~* Willingness to spend about 2h in the clinical exp. lab.~Exclusion Criteria:~* Acute airway infection~* History of asthma~* Smokers~* Pregnancy~* Abnormal lab. screen with liver function tests, Creat./BUN, CBC, blood glucose~* Anxiety or mood disorder~* Any chronic disease (incl. lung \& heart disease, cancer, endocrine disorder)~* Mental retardation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
- 2 (Type: ACTIVE_COMPARATOR): Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
- 3 (Type: ACTIVE_COMPARATOR): Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented atrial arrhythmia after valvular and/or coronary artery bypass graft surgery~Exclusion Criteria:~* Unstable Class IV heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for clinically significant symptoms of depression or anxiety using self-report measures used in screening for depression, as well as interviewer administered measures to ensure symptoms are not transitory and have been present for at least two weeks.~* Is familiar with the use of mobile phones~* Has an Android phone and is willing download the IntelliCare apps on their own device~* Is able to speak and read English~* Is at least 19 years of age~* Is able to give informed consent~Exclusion Criteria:~* Has visual, hearing, voice, or motor impairment that would prevent completion of study and treatment procedures~* Has any psychiatric condition for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous (e.g., psychotic disorders, bipolar disorders, dissociative disorders, obsessive compulsive disorder, severe post traumatic stress disorder, etc.).~* Exhibits severe suicidality, including ideation, plan, and intent.~* Currently receiving psychotherapy or planning to receive psychotherapy during the 8 weeks of the study.~* Participants who have been on an antidepressant or anxiolytic medication with no dose changes for 2 weeks and do not intend to change the dose will be eligible. Those who have been on the antidepressant or anxiolytic for less than 2 weeks or intend to have their medication optimized will be asked to wait for screening until they meet the 2-week criterion.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 8-Week Single Arm Field Trial (Type: EXPERIMENTAL): Use of IntelliCare program for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete